文献速递慢性静脉疾病

种族/民族与静脉消融结局的关系

Race/ethnicity and outcomes of venous ablation procedures.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-08-06

该单中心回顾性研究分析了2012至2022年13335例腔内热消融手术,比较不同种族/民族间EHIT和再通率。黑种人EHIT风险较高(OR 1.92),亚裔再通风险较高(OR 1.65),总体成功率95%-96%。

要点

  • 黑种人患者EHIT发生率3.0%,显著高于白种人1.7%(P < .001)。
  • 多变量分析显示黑种人EHIT风险OR 1.92,亚裔再通风险OR 1.65。
  • 总体手术成功率在各组间均达95%-96%,消融安全有效。

核心结论

  • 腔内消融在不同种族/民族中安全有效,总体成功率95%-96%。
  • 黑种人EHIT风险较高且就诊时疾病更晚期,亚裔再通风险略高。

研究设计与样本

  • 单中心回顾性分析2012至2022年13335例腔内热消融手术(射频8187例,激光5148例),共3218例患者。
  • 女性占67.1%,平均随访25.8±12.9个月(范围3-72个月)。

主要发现

  • EHIT发生率黑种人3.0%、亚裔2.6%、白种人1.7%、西班牙裔1.4%,黑种人与白种人差异显著(P < .001)。
  • 手术成功率(无EHIT或再通)亚裔96.1%、黑种人95.2%、西班牙裔96.1%、白种人96.2%。
  • 多变量分析黑种人EHIT风险OR 1.92(P < .001),亚裔再通风险OR 1.65(P = .045)。
  • 再通预测因素包括CEAP 6级(P < .05);大隐、前隐或小隐静脉消融较穿通静脉有保护作用(均P < .001)。
  • EHIT预测因素包括年龄较大(P < .0001)和既往再通(P < .0001);激光消融较射频显著降低EHIT风险(P < .0001)。

临床怎么用

  • 针对黑种人患者加强术后EHIT监测,对亚裔患者关注再通风险。
  • 改善少数族裔的早期就医机会以应对就诊时疾病更晚期的问题。

局限性

  • 单中心回顾性设计可能限制结论外推。
  • 随访时间范围为3-72个月,部分患者随访可能不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and safety of endovenous ablation across racial and ethnic groups by comparing rates of endovenous heat-induced thrombosis (EHIT) and recanalization. METHODS: We retrospectively analyzed 13,335 endothermal ablation procedures (radiofrequency or laser) performed from 2012 to 2022 at a single outpatient center. Patient demographics, including self-identified race/ethnicity (such as Asian, Black, Hispanic, and White), were recorded. Postprocedural duplex ultrasound study was conducted at 3 to 7 days, 3 to 6 months, and then every 6 to 12 months. EHIT (classes 1-4) and recanalization of the treated vein were identified on follow-up imaging. Outcomes were compared across racial/ethnic groups using univariable and multivariable logistic regression. RESULTS: Among 13,335 ablations (8187 radiofrequency and 5148 laser) in 3218 patients, 67.1% were performed in women. Mean follow-up was 25.8 ± 12.9 months (range, 3-72 months). EHIT incidence was highest in Black patients (3.0%), followed by Asian (2.6%), White (1.7%), and Hispanic (1.4%) patients; the difference between Black and White patients was significant (P < .001), whereas other pairwise comparisons were not. Procedural success (no EHIT or recanalization) was high and comparable across groups: 96.1% in Asians, 95.2% in Blacks, 96.1% in Hispanics, and 96.2% in Whites. On multivariable analysis, Black race was associated with higher EHIT risk (odds ratio, 1.92; P < .001), and Asian race with higher recanalization risk (odds ratio, 1.65; P = .045). Additional predictors of recanalization included advanced disease (Clinical, Etiologic, Anatomic, and Pathophysiologic class 6; P < .05), whereas the ablation of the great, anterior, or small saphenous veins was protective compared with perforator veins (all P < .001). Predictors of EHIT included older age (P < .0001) and previous recanalization (P < .0001), whereas laser ablation was associated with a significantly lower EHIT risk compared with radiofrequency (P < .0001). Baseline disease severity also varied: Black patients were more likely to present with advanced disease (Clinical, Etiologic, Anatomic, and Pathophysiologic class, 5-6) than Hispanic and Asian patients (P < .0001). CONCLUSIONS: Endovenous ablation is a safe and effective treatment for chronic venous insufficiency across different racial/ethnic groups, with overall success rates of 95% to 96%. However, racial differences were observed in complication rates and baseline severity: Black patients had higher EHIT risk and more advanced disease at presentation, whereas Asian patients had a slightly higher risk of recanalization. These findings highlight the need for tailored postablation surveillance and improved early access to care to address differences in minority populations.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Kibrik P, Kwon J, Singh N, et al. Race/ethnicity and outcomes of venous ablation procedures. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42413658. doi:10.1016/j.jvsv.2026.102576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。